Source-grounded facts extracted from Outset Medical, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Outset Medical, Inc. updated its 2026 guidance (reaffirmed).
“The Company is reiterating previously issued guidance for 2026, and plans to provide additional detail regarding the 2026 financial impact of the Amendment later in the year once it has visibility to the timing and ramp of the implementation.”
Outset Medical, Inc. amended Refresh Amendment with HCA Management Services, L.P. valued at approximately $40 million (effective 2026-06-14).
“On June 14, 2026, Outset Medical, Inc., (the “Company”) entered into the Refresh Amendment (the “Amendment”) to the Purchasing Agreement with HCA Management Services, L.P. (“HCA”), dated May 1, 2020, as amended (collectively, the “Agreement”). Under the terms of the Amendment, the parties have agreed, among other things, for HCA to refresh its existing fleet of Tablo Hemodialysis Systems by purchasing new Tablo Hemodialysis Systems commencing in 2026 through the end of 2028, for an aggregate contract value, net of rebates and allowances, of approximately $40 million.”
Outset Medical, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
“Proposal Three: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following vote:”
Outset Medical, Inc. shareholders approved Advisory Vote on Named Executive Officer Compensation at the 2026-06-04 meeting.
“Proposal Two: Advisory Vote on Named Executive Officer Compensation The proposal to approve the 2025 compensation of the Company’s named executive officers as disclosed in its 2026 proxy statement on a non-binding advisory basis was approved by the following vote:”
Outset Medical, Inc. shareholders approved Election of Class III Directors at the 2026-06-04 meeting.
“Proposal One: Election of Class III Directors Each of Brent D. Lang and Karen Prange was elected to serve as a class III director to hold office until the Company’s 2029 annual meeting of stockholders and until the election and qualification of his or her successor.”
Marc Nash departed as Executive Vice President, R&D, Operations and Service at Outset Medical, Inc..
“On May 26, 2026, Marc Nash informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company and his role as Executive Vice President, R&D, Operations and Service, effective June 5, 2026, to pursue other professional opportunities.”
Outset Medical, Inc. reported the first quarter ended March 31, 2026 results: revenue $27.9 million, net income Net loss was $19.0 million. Guidance reaffirmed.
“Net revenue totaled $27.9 million, a decrease of 6% compared to $29.8 million in the first quarter of 2025.”
Renee Gaeta was appointed as Chief Financial Officer at Outset Medical, Inc..
“On May 30, 2025, the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”) appointed Renee Gaeta as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 3, 2025.”
Kevin O'Boyle was appointed as new member of the Board and as a member and Chair of the Audit Committee at Outset Medical, Inc..
“On May 12, 2025, the Board appointed Kevin O’Boyle as a new member of the Board and as a member and Chair of the Audit Committee of the Board, with such appointment effective May 14, 2025.”
Dale E. Jones departed as member of the Board of Directors at Outset Medical, Inc..
“On May 10, 2025, Dale E. Jones, a member of the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”), stepped down from the Board, effective May 14, 2025.”
Outset Medical, Inc.: Outset Medical, Inc. filed an amendment to its Amended and Restated Certificate of Incorporation to effect a one-for-fifteen reverse stock split of its common stock, effective March 20, 2025 (effective 2025-03-20).
“On March 20, 2025, Outset Medical, Inc., a Delaware corporation (the “ Company ”), effected a one-for-fifteen reverse stock split (“ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 (the “ Common Stock ”).”
Outset Medical, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“February 24, 2025, the Company received a second notice (the “Notice”) from Nasdaq of failure to comply with the minimum bid price requirement. The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market, which will continue to trade on the Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until August 25, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s”
Outset Medical, Inc.: Filed Certificate of Designation for Series A Non-Voting Convertible Preferred Stock, establishing rights, preferences, and limitations (effective 2025-01-07).
“On January 7, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the "Certificate of Designations") in connection with the Private Placement.”
Jim Hinrichs resigned as Director and Audit Committee Chair at Outset Medical, Inc..
“On August 15, 2024, Jim Hinrichs, a member of the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”), notified the Company of his decision to resign from the Board and his role as Audit Committee Chair, effective immediately.”
Outset Medical, Inc. reported full year 2024 results: revenue $145 million to $153 million. Guidance reaffirmed.
“Outset reaffirmed its previously provided guidance for 2024 including revenue of $145 million to $153 million, growing 12% to 18% over 2023, and non-GAAP gross margin in the low-30% range for the full year 2024, exiting the year in the mid-30% range for the fourth quarter.”
Outset Medical, Inc. reported first quarter ended March 31, 2024 results: net income $(39.9) million, EPS $(0.78) per share.
“Revenue for the first quarter of 2024 was $28.2 million compared to $33.5 million in the first quarter of 2023”
Jean-Olivier Racine departed as Chief Technology Officer at Outset Medical, Inc..
“Jean-Olivier Racine will depart from his role as the Company's Chief Technology Officer, effective May 17, 2024, in connection with the workforce reduction plan described in Item 8.01 below.”
Brent D. Lang was appointed as Director at Outset Medical, Inc..
“On March 10, 2024, the Board appointed Brent D. Lang as a new member of the Board and as a member of the Audit Committee of the Board, with such appointment effective March 12, 2024.”
Catherine Szyman resigned as Director at Outset Medical, Inc..
“On March 8, 2024, Catherine Szyman, a member of the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”), resigned from the Board in preparation for her pending role as Chief Executive Officer of Edwards Lifesciences’ Critical Care spinoff, with such resignation effective March 12, 2024.”
Outset Medical, Inc. updated its fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).
“On February 21, 2024, Outset Medical, Inc. (the “Company”) issued a press release and will hold its fourth quarter and full year 2023 earnings conference call announcing the Company’s financial results for the quarter and year ended December 31, 2023.”
Steve Williamson departed as Chief Commercial Officer at Outset Medical, Inc..
“On February 16, 2024, Steve Williamson informed the Company of his decision to depart from the Company and his role as Chief Commercial Officer, effective March 1, 2024, to become the CEO of another publicly traded medical device company.”
Outset Medical, Inc. reported the full year 2024 results: revenue between $145 million to $153 million. Guidance initiated.
“Outset expects 2024 revenue to be between $145 million to $153 million”
Outset Medical, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $30.5 million. Guidance initiated.
“year ended December 31, 2023, and provided 2024 financial guidance. Unaudited Fourth Quarter and Year End Results, and Recent Highlights • Revenue in the fourth quarter totaled $30.5 million, bringing revenue for 2023 to $130 million, a 13% increase compared to $115 million in 2022. • Period-end installed base increased 34% year-over-year to approximately 5,350”
Outset Medical, Inc. incurred term loan of approximately $66.5 million term loans with SLR Investment Corp..
“On January 2, 2024, Outset Medical, Inc. (the Company) borrowed and received approximately $66.5 million term loans under its existing term loan facility pursuant to a loan and security agreement among SLR Investment Corp., as collateral agent, the lenders from time to time party thereto and the Company (the SLR Term Loan Facility). After giving effect to such borrowing and the recent borrowing the Company made on December 11, 2023, the outstanding principal amount of the SLR Term Loan Facility is $200.0 million.”
Outset Medical, Inc. incurred term loan of $100.0 million Term B Loans will be available in two tranches consisting of (i) Term B-1 Loans in the aggregate amount o with SLR Investment Corp., as collateral agent, the lenders from time to time party thereto.
“The SLR Term Loan Amendment provides that the $100.0 million Term B Loans will be available in two tranches consisting of (i) Term B-1 Loans in the aggregate amount of approximately $33.5 million and (ii) Term B-2 Loans in the aggregate amount of approximately $66.5 million.”
Outset Medical, Inc. incurred term loan of Term B-1 Loans in the aggregate amount of approximately $33.5 million with SLR Investment Corp., as collateral agent, the lenders from time to time party thereto.
“the Company borrowed and received the entire Term B-1 Loans from the Term Loan Lenders.”
Outset Medical, Inc. amended First Amendment to Loan and Security Agreement with SLR Investment Corp. valued at Amendment provides for $100.0 million Term B Loans in two tranches (B-1 ~$33.5M, B-2 ~$66.5M); borro (effective 2023-12-11).
“On December 11, 2023 (the Amendment Effective Date), the Company amended the SLR Term Loan Facility pursuant to a First Amendment to Loan and Security Agreement (the SLR Term Loan Amendment) among the Collateral Agent, the Term Loan Lenders and the Company.”
Outset Medical, Inc. reported third quarter ended September 30, 2023 results: revenue Revenue for the third quarter was $30.4 million, net income Net loss was ($46.2) million, EPS ($0.93) per share. Guidance reaffirmed.
“technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2023. Revenue for the third quarter was $30.4 million, a 9% increase over revenue of $27.8 million in the third quarter of 2022, and gross margin was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% on a non-GAAP basis in the”
Outset Medical, Inc. updated its third quarter ended Sept. 30, 2023 guidance (reaffirmed).
“On October 12, 2023, Outset Medical, Inc. (the “ Company ”) issued a press release announcing expected revenue and gross margin for the third quarter ended September 30, 2023, as well as updated financial guidance for 2023 revenue.”
Outset Medical, Inc. reported the second quarter ended June 30, 2023 results: revenue $36.0 million, net income ($44.0) million, EPS ($0.90) per share. Guidance reaffirmed.
“to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Recorded net revenue of $36.0 million in the second quarter, a 44% increase compared to $25.1 million in the second quarter of 2022, and an 8% increase compared to $33.5 million in the first quarter of 2023. •”
Outset Medical, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-31 meeting.
“Proposal Three: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote: For Against Abstain Broker Non-Votes 42,975,493 29,313 31,761 —”
Outset Medical, Inc. shareholders approved Advisory Vote on Named Executive Officer Compensation at the 2023-05-31 meeting.
“Proposal Two: Advisory Vote on Named Executive Officer Compensation The Company’s stockholders approved, on a non-binding advisory basis, the 2022 compensation of the Company’s named executive officers as disclosed in its 2023 proxy statement by the following vote: For Against Abstain Broker Non-Votes 37,566,238 2,837,679 28,088 2,604,562”
Outset Medical, Inc. shareholders approved Election of Class III Directors at the 2023-05-31 meeting.
“Proposal One: Election of Class III Directors Each of Jim Hinrichs, Andrea L. Saia and Catherine Szyman was elected to serve as a class III director to hold office until the Company’s 2026 annual meeting of stockholders and until the election and qualification of his or her successor. Votes were cast as follows: For Withheld Broker Non-Votes Jim Hinrichs 31,328,771 9,103,234 2,604,562 Andrea L. Saia 32,411,431 8,020,574 2,604,562 Catherine Szyman 30,893,629 9,538,376 2,604,562”
Outset Medical, Inc. reported first quarter ended March 31, 2023 results: revenue $33.5 million, net income ($44.0) million, EPS ($0.90) per share. Guidance raised.
“to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights • Recorded net revenue of $33.5 million in the first quarter, a 9.5% increase compared to $30.6 million in the first quarter of 2022, and a 4.6% increase compared to $32.0 million in the fourth quarter of 2022 •”
Outset Medical, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue Revenue for the fourth quarter of 2022 was $32.0 million, net income Net loss was ($41.4) million. Guidance reaffirmed.
“Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2022.”
Martin Vazquez departed as Chief Operating Officer at Outset Medical, Inc..
“On February 13, 2023, Martin Vazquez informed the Company of his decision to retire from his role as Chief Operating Officer of the Company effective April 3, 2023 to pursue personal opportunities.”
Outset Medical, Inc. updated its 2023 guidance (initiated).
“Outset expects 2023 revenue to be between $140 million to $150 million, growing approximately 22% to 30% over expected revenue for 2022. Non-GAAP gross margin is expected to expand to approximately 20% for the full year 2023 and exit the year in the mid-20% range for the fourth quarter of 2023.”
Outset Medical, Inc. reported the fourth quarter and fiscal year ended December 31, 2022 results: revenue approximately $31.5 million.
“revenue for the fourth quarter and fiscal year ended December 31, 2022. Fourth Quarter and Year End Highlights • Revenue in the fourth quarter is expected to be approximately $31.5 million, a 13% increase compared to $27.8 million in the third quarter of 2022 • Revenue for 2022 is expected to be approximately $115 million, a 12% increase compared to $102.6 million”
Outset Medical, Inc. reported the third quarter ended September 30, 2022 results: revenue $27.8 million, net income ($40.8) million, EPS ($0.85) per share. Guidance raised.
“specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Outset Medical Reports Third Quarter 2022 Financial Results Revenue Grows 10.8% from Q2 to $27.8 million; Gross Margin Expands to 15.6% 2022 Revenue Guidance Raised to $111 million to $113 million San Jose, CA – November 8, 2022 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the”
Outset Medical, Inc. incurred revolving credit of $25.0 million with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL at one-month term SOFR (subject to a 2.75% floor), plus 3.20%.
“The SLR Revolving Credit Agreement provides for an asset-based revolving credit facility with aggregate revolving commitments of $25.0 million (the Initial Revolver Commitment).”
Outset Medical, Inc. incurred term loan of up to $250.0 million with SLR Investment Corp. at one-month term SOFR (subject to a 2.75% floor), plus 5.15% maturing November 1, 2027.
“Milestone), on or before June 30, 2024 and the Additional Tranche (as defined below) under the SLR Revolver has been approved, the Company will be permitted to borrow up to $250.0 million under the SLR Credit Facilities. If the Company achieves a subsequent additional net revenue milestone, calculated on a trailing six month basis (Second Revenue Milestone), on or”
Outset Medical, Inc. entered into SLR Revolving Credit Agreement with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender valued at $25.0 million (effective 2022-11-03).
“The SLR Revolving Credit Agreement provides for an asset-based revolving credit facility with aggregate revolving commitments of $25.0 million (the Initial Revolver Commitment).”
Outset Medical, Inc. entered into SLR Loan Agreement with SLR Investment Corp., as collateral agent, and the lenders from time to time party thereto valued at up to $250.0 million (effective 2022-11-03).
“Pursuant to the terms and conditions of the SLR Loan Agreement, the Term Loan Lenders agreed to extend term loans to the Company in an aggregate principal amount of up to $250.0 million, comprised of (i) a term loan of $100.0 million (the Term A Loan), (ii) one or more term loans (in minimum increments of $20.0 million each) in the aggregate of up to $100.0 million (each, a Term B Loan) and (iii) one or more term loans in the aggregate of up to $50.0 million (each, a Term C Loan).”
Dale E. Jones was appointed as Director at Outset Medical, Inc..
“On April 21, 2022, the Board of Directors (the “ Board ”) of Outset Medical, Inc. (the “ Company ”) determined to increase the size of the Board from seven (7) directors to eight (8) directors and appointed Dale E. Jones as a new member of the Board and as a member of the Compensation Committee of the Board, with such appointment to be effective immediately.”
Nabeel Ahmed was appointed as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at Outset Medical, Inc..
“On August 5, 2021, the Company announced the Board of Director’s approval of Mr. Ahmed’s transition to the permanent role of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective July 30, 2021”
Nabeel Ahmed was appointed as Interim Chief Financial Officer at Outset Medical, Inc..
“On June 29, 2021, the Company's Board of Directors appointed Nabeel Ahmed, the Company's Vice President, Finance, to serve as Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company effective as of the Effective Date”
Rebecca Chambers resigned as Chief Financial Officer at Outset Medical, Inc..
“On June 28, 2021, Rebecca Chambers notified the Company of her decision to resign from her role as the Company's Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity, with such resignation effective as of July 16, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.